Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8,450 | 10 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Orion Corporation | $8,450 | 10 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $3,125 | 4 | Orion Corporation ($3,125) |
| 2019 | $5,325 | 6 | Orion Corporation ($5,325) |
All Payment Transactions
10 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/09/2020 | Orion Corporation | — | — | Cash or cash equivalent | $750.00 | Research |
| Study: Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | ||||||
| 05/11/2020 | Orion Corporation | — | — | Cash or cash equivalent | $625.00 | Research |
| Study: Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | ||||||
| 03/30/2020 | Orion Corporation | — | — | Cash or cash equivalent | $750.00 | Research |
| Study: Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | ||||||
| 01/20/2020 | Orion Corporation | — | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | ||||||
| 12/09/2019 | Orion Corporation | — | — | Cash or cash equivalent | $750.00 | Research |
| Study: Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | ||||||
| 09/16/2019 | Orion Corporation | — | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | ||||||
| 09/16/2019 | Orion Corporation | — | — | Cash or cash equivalent | $700.00 | Research |
| Study: Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | ||||||
| 05/20/2019 | Orion Corporation | — | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | ||||||
| 03/11/2019 | Orion Corporation | — | — | Cash or cash equivalent | $875.00 | Research |
| Study: Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | ||||||
| 01/28/2019 | Orion Corporation | — | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | Orion Corporation | $8,450 | 10 |
About Patrick Mcbride, MD MPH
Patrick Mcbride, MD MPH is a Hypertension Specialist healthcare provider based in Madison, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1851367882.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Patrick Mcbride, MD MPH has received a total of $8,450 in payments from pharmaceutical and medical device companies, with $3,125 received in 2020. These payments were reported across 10 transactions from 1 company. The most common payment nature is "" ($8,450).
Practice Information
- Specialty Hypertension Specialist
- Other Specialties Cardiovascular Disease
- Location Madison, WI
- Active Since 02/28/2006
- Last Updated 07/10/2017
- Taxonomy Code 207RH0005X
- Entity Type Individual
- NPI Number 1851367882
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.